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Abstract
Background: This study will assess measures of vascular health and inflammation in Aboriginal Australian adults
with chronic kidney disease (CKD), and determine if intensive periodontal intervention improves cardiovascular
health, progression of renal disease and periodontal health over a 24-month follow-up.
Methods: The study will be a randomised controlled trial. All participants will receive the periodontal intervention
benefits, with the delayed intervention group receiving periodontal treatment 24 months following baseline.
Inclusion criteria include being an Aboriginal Australian, having CKD (a. on dialysis; b. eGFR levels of <60 mls/min/1.73 m2
(CKD Stages 3 to 5); c. ACR ≥30 mg/mmol irrespective of eGFR (CKD Stages 1 and 2); d. diabetes plus albuminuria
(ACR ≥ 3 mg/mmol) irrespective of eGFR), having moderate or severe periodontal disease, having at least 12
teeth, and living in Central Australia for the 2-year study duration. The intervention involves intensive removal of
dental plaque biofilms by scaling, root-planing and removal of teeth that cannot be saved. The intervention will
occur in three visits; baseline, 3-month and 6-month follow-up. The primary outcome will be changes in carotid
intima-media thickness (cIMT). Secondary outcomes will include progression of CKD or death as a consequence
of CKD/cardiovascular disease. Progression of CKD will be defined by time to the development of the first of:
(1) new development of macroalbuminuria; (2) 30 % loss of baseline eGFR; (3) progression to end stage kidney
disease defined by eGFR <15 mLs/min/1.73 m2; (4) progression to end stage kidney disease defined by commencement
of renal replacement therapy. A sample size of 472 is necessary to detect a difference in cIMT of 0.026 mm (SD 0.09)
at the significance criterion of 0.05 and a power of 0.80. Allowing for 20 % attrition, 592 participants are necessary at
baseline, rounded to 600 for convenience.
Discussion: This will be the first RCT evaluating the effect of periodontal therapy on progression of CKD and
cardiovascular disease among Aboriginal patients with CKD. Demonstration of a significant attenuation of CKD
progression and cardiovascular disease has the potential to inform clinicians of an important, new and widely available
strategy for reducing CKD progression and cardiovascular disease for Australia’s most disadvantaged population.
Trial registration: This trial is registered with the Australian New Zealand Clinical Trial Registry ANZCTR12614001183673.
Background
Aboriginal Australian health
Aboriginal Australians experience poor health relative to
their non-Aboriginal counterparts [1]. They have 15–
20 years shorter life expectancy, much higher levels of
chronic diseases, and are more likely to experience disabil-
ity and reduced quality of life due to ill health. There is a
heavy burden of infectious diseases as well as high rates of
metabolic risks among the Aboriginal population [2]. Along
with other chronic conditions, dental disease and chronic
kidney disease levels in the Aboriginal population are
equivalent to those in the poorest nations [3, 4]. There are
many reasons why such conditions are common. Financial
barriers are frequently cited, together with lack of service
access, cultural factors, global risk factors and social deter-
minants. While recognising their importance, this proposal
does not address these influences, but rather focuses on the
role of oral health, specifically periodontal disease, in Abori-
ginal renal health.
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Chronic kidney disease (CKD); the problem
CKD is characterised by a progressive loss of renal func-
tion over a period of months or years culminating with
end stage kidney disease (ESKD), when a person will re-
quire ongoing dialysis or a kidney transplant to stay
alive, being the final stage of this progressive loss [5].
Like most other chronic diseases, the burden of CKD
and consequent ESKD in Australia is increasing. It is
estimated that approximately 12 % of Australians have
either reduced kidney function or other markers of
kidney damage [6]. There is clear evidence across the
spectrum of CKD of an excess burden of premature
comorbidity and mortality due to cardiovascular disease
(CVD). CKD contributes to approximately 15 % of total
Australian hospitalisations, with current medical costs for
ESKD patients amounting to more than $1 billion annu-
ally [7]. Overall, patients with CKD have a mortality rate
around 4 times that of their non-CKD counterparts [8].
CKD; the measurement
Common measures used in the assessment of CKD are the
urinary albumin-to-creatinine ratio (ACR) and glomerular
filtration rate (GFR). Albuminuria (or microalbuminuria) is
defined as urine ACR ≥3 and ≤30 mg/mmol, while protein-
uria (macroalbuminuria) is defined as ACR ≥ 30 mg/mmol
[9]. Because GFR cannot be directly measured in usual
clinical practice, it is estimated from equations using serum
creatinine, age, sex and body size [10]. Estimated GFR is
referred to as eGFR. Both reduced eGFR and level of pro-
teinuria are independent risk factors for CVD morbidity
and mortality, and for progression of ESKD.
CKD among Aboriginal Australians
Findings from the 2012–13 Australian Aboriginal and
Torres Strait Islander Health Survey indicate that the
prevalence of CKD amongst Australian Indigenous adults
is approximately 18 % [11]. The National Biomedical Risk
Factor Survey (which included approximately 3300 Indi-
genous adults) revealed that the prevalence of CKD was
34 % in remote locations, and that approximately
53 % of people with diabetes had signs of CKD. In
Central Australia, more than 40 % of Aboriginal
Health Service attendees were reported as having micro or
macroalbuminuria and 40 % were reported as having re-
duced eGFR [12]. Dialysis is the leading cause of hospital-
isation for Aboriginal Australians—constituting 42 % of all
admissions [8]. Recent literature suggests that the preva-
lence nationwide of Aboriginal Australians with ESKD
resulting in renal replacement therapy is around 10 times
that of non-Aboriginal Australians [4]. Aboriginal Austra-
lians with ESKD are younger than their non-Aboriginal
counterparts and there is high comorbidity. There is
regional variability, with Aboriginal Australians living in
remote Northern Territory communities having 20 times
the prevalence of renal replacement therapy than remote-
living non-Aboriginal Australians [13, 14]. Renal replace-
ment therapy is strongly associated with socio-economic
disadvantage [15, 16].
Periodontal disease
Periodontal disease is inflammation of the tissues sur-
rounding teeth and results from a complex interplay
between bacteria and host risk factors. Periodontal or-
ganisms flourish in the presence of inflammation, enab-
ling them to invade host tissues and to gain direct access
to the circulation [17]. The constant exposure of the
vasculature to these pathogens provides an opportunity
for endothelial inflammatory activation and functional
impairment [18]. Clinically, this manifests as deepening
of the epithelial attachment around teeth, loss of peri-
odontal attachment and, ultimately, tooth loosening.
The total burden of this infection may be significant;
specifically, it may account for a portion of the proposed
risk for CKD and other systemic conditions that share
an underlying inflammatory response as a common
component of pathogenesis [17].
Periodontal disease and Aboriginal Australians
Although representative national-level data are unavail-
able, estimates from convenience samples indicate that
periodontal disease is a substantial problem among Abori-
ginal Australians. The prevalence of periodontal disease
among Aboriginal participants seeking care at the Redfern
Aboriginal Medical Service was around 60 % [19], while
the prevalence was approximately 90 % in a recent
convenience sample in the Northern Territory [20].
CKD and periodontal disease
Periodontal disease has emerged as a non-traditional risk
factor for CKD [21]. In nationally-representative cross-
sectional surveys, there is increasing evidence of associa-
tions between CKD and periodontal disease, with a
higher proportion of those with CKD having periodontal
disease and vice versa [22–24]. Biological plausibility for
considering periodontal disease as a CKD risk factor is
derived from the potential role of the inflammatory re-
sponse to periodontal disease in the chronic systemic
inflammatory burden (for example, increased C-reactive
protein (CRP) levels) associated with CKD [25–28]. The
local tissue destructive immuno-inflammatory response to
periodontal pathogens, their products and inflammatory
cytokines are believed to contribute to the chronic sys-
temic inflammatory burden of periodontal disease [29, 30].
Can CKD progression be reduced by periodontal therapy?
Few studies have investigated the effect of periodontal
treatment on kidney function. In a prospective co-
hort of haemodialysis patients in Thailand, successful
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non-surgical periodontal treatment resulted in marked
reductions in CRP (mean change −3.2 mg/L) after two
months [31]. A similar reduction in CRP following peri-
odontal treatment was reported among patients with CKD
in an Italian-based study (mean change −2.1 mg/L) [31].
Graziani and colleagues, in a prospective cohort including
20 healthy people, reported that successful periodontal
treatment improved cystatin C levels but had no ef-
fect on eGFR after 3 months (mean change −1.4 mL/
min/1.73 m2) [32]. In a non-randomised clinical trial
involving 40 people, Artese et al. reported that periodontal
therapy significantly improved eGFR among patients with
CKD (mean change 4.2 mL/min/1.73 m2), whereas there
were no differences in serum creatinine [33]. A reduction
in proteinuria was obtained following a periodontal inter-
vention among 11 patients with IgA nephropathy, but all
patients were children [34]. There are substantial short-
comings with each of these studies; all have small sample
sizes, most have only one periodontal therapy session and
none were randomised controlled trials. There are also
considerable differences in patient populations; the sever-
ity of CKD among our Aboriginal group will be greater,
suggesting the possibility of increased efficacy of the peri-
odontal treatment. Shortcomings aside, the evidence sug-
gests that periodontal health may improve renal health,
warranting a more robust clinical trial study design.
Can CVD progression be reduced by periodontal therapy?
There is some evidence that CVD is influenced by peri-
odontal health. Piconi et al. reported a diminution in
carotid intima media thickness (cIMT; an established,
non-invasive measure of atherosclerotic burden previ-
ously validated against histology specimens. cIMT is
associated with cardiac risk factors, and predicts incident
cardiovascular events) [35–39] 12 months following
periodontal treatment among 35 otherwise healthy adults
(mean change −0.12 mm, P < 0.001) [38]. In our recent
periodontal intervention among Aboriginal adults in the
Northern Territory, cIMT decreased in those rando-
mised to the periodontal intervention (−0.026 mm
[95 % CI −0.048, −0.003], P = 0.03) compared to control
group [39]. The magnitude of the reduction in carotid
IMT with periodontal intervention in this trial was equiva-
lent to the effects of reversal of 4 years of aging, 8 kg/m2
lower body mass index or 25 mmHg lower systolic blood
pressure. Mercanoglu and colleagues provided the first
evidence that treating periodontal disease results in a
functional improvement in cardiovascular status [40].
Among 54 otherwise healthy patients, flow mediated dila-
tion (FMD)—a measure of endothelial function represent-
ing an important early stage of atherosclerosis [41], with
its presence in coronary or peripheral vessels constituting
an independent predictor of cardiovascular events [42],
improved from 8.4 % to 17.7 % 6 weeks post periodontal
treatment (P < 0.01). In an RCT, Tonetti et al. demon-
strated improved FMD after 2 months (absolute difference
0.9 %; P = 0.02) and 6 months (absolute difference 2.0 %;
P < 0.001) for the intervention group who received intense
periodontal therapy [43]. The degree of improvement was
associated with improvement in measures of periodontal
disease (r = 0.29, P = 0.003).
Aims and hypotheses
The goals are to assess levels of periodontal disease
among a group of Aboriginal adults with CKD and to
determine if comprehensive periodontal therapy might
reduce progression of CKD, non-invasive measures of
cardiovascular disease (CVD) or CKD/CVD-related death
amongst people with CKD over 6 to 24 months. The
specific aims and hypotheses are:
Aim 1: To describe the extent and severity of periodontal
disease in a group of Aboriginal adults with CKD.
Hypothesis: The extent and severity of periodontal
disease in an Aboriginal population with CKD will be
high compared with national-level indicators.
Aim 2: To examine the effects of a comprehensive
periodontal intervention among an Aboriginal
population with CKD.
Hypothesis: Exposure to a comprehensive periodontal
intervention will reduce progression of CKD, non-invasive




This will be a delayed intervention RCT, with all partici-
pants ultimately receiving the periodontal intervention
benefits (Fig. 1).
Ethical approval
The study was approved by the University of Adelaide
Human Research Ethics Committee and the Central
Australian Human Research Ethics Committee. Written
informed consent will be obtained from study partici-
pants before their involvement in the trial.
Inclusion criteria
Aboriginal people aged 18+ years who have lived in the
study location for 2+ years, and who plan to live at their
current location for the next 2 years, with CKD (i. on
dialysis; ii. eGFR levels of <60 mls/min/1.73 m2 (CKD
Stages 3 to 5); iii. ACR ≥30 mg/mmol irrespective of
eGFR (CKD Stages 1 and 2); iv. diabetes plus albumin-
uria (ACR ≥ 3 mg/mmol) irrespective of eGFR), with at
least 12 teeth at baseline and having moderate or severe
periodontal disease will be invited to take part in the
study. Periodontal disease will be assessed using the US
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Centers for Disease Control and Prevention and the
American Academy of Periodontology definitions, whereby
a case of moderate periodontitis is considered as the
presence of either two sites between adjacent teeth
with 4 mm+ attachment loss or at least two such sites with
5 mm+ pockets, and severe periodontitis as having at least
two sites between adjacent teeth with 6 mm+ attachment
loss and at least one 5 mm+ pocket [44].
Randomisation
Randomisation will be developed by biostatisticians at
the Australian Research Centre for Population Oral
Health using a random number generator. Randomly se-
lected block sizes of 4, 6 and 8 will be used. This will
guarantee an equal number of participants in each inter-
vention arm within the blocks, with any differences in
confounders and other characteristics being then due to
chance. Randomisation will be done using field staff lap-
top computers. The field staff will be required to register
the participants in the trial prior to identifying the ran-
domised group. These data will be unable to be altered,
thus allowing the randomisation process to be audited.
Periodontal intervention
The periodontal intervention will be based on the tech-
nique described by Tonetti and colleagues [43]. This
involves intensive removal of subgingival dental plaque
biofilms by scaling, root-planing and removal of teeth
that cannot be saved, following administration of local
anaesthesia. The intervention will be performed by regis-
tered oral health professionals and will occur in three
visits; baseline, 3 months and 6 months post-baseline.
Location
The study will be undertaken in Alice Springs, Northern
Territory of Australia.
Engagement, recruitment and retention
This study will rely on commitment from the Alice
Springs primary and tertiary health care sector. Conveni-
ently, the Alice Springs Renal Dialysis Unit is located a
few metres from the Alice Springs-based Northern
Territory Oral Health Services. Specific recruitment
strategies will include: establishing service agreements
with the key Aboriginal community-controlled health
and mainstream government health services in Alice
Springs; liaising with community champions previously
involved in Alice Springs-based research projects; en-
gaging with key community stakeholder groups; encour-
aging word-of-mouth spread of knowledge about the
study; advertisements in local newspapers and radio
shows; flyers in post boxes in high-density Aboriginal
locations and presentations made to community
groups. A passive snowballing technique will also be
Fig. 1 Study plan schema
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employed, with participants asked to contact any
Aboriginal friends, family and peers who may be in-
terested in partaking. Retention strategies will involve:
(1) employing staff who are committed to following up
participants despite challenges in doing so; (2) ensuring
participants are contacted on a regular basis to check ac-
curacy of contact details; (3) maintaining relationships
with appropriate stake holders; (4) ascertaining contact
details of three key personnel who may know the where-
abouts of participants should the study team be unable to
contact them; (5) sending birthday and Christmas cards to
participants; and (6) faciliating one-on-one relationships
between study staff and participants, with study staff
ideally seeing each of their participants for each phase of
the research. We will allow 2 years for recruitment.
Follow up
Participants will be followed for 24 months after ran-
domisation. Because this is a pragmatic study evaluating
the delivery of periodontal care, rather than therapeutic
agents, an open design is necessary. Appropriate care
will be taken to ensure standardised, and where feasible,
blinded outcome evaluation—“PROBE” design [45]. During
follow-up, all study participants will attend clinic visits at
6 months, 12 months and at 24 months.
Sample size
Based on a recent study of Australian Aboriginal adults
with periodontal disease, it was estimated that a sample
size of 472 would be necessary to detect a difference in
cIMT of 0.026 mm (SD 0.09) [46] at the significance
criterion of 0.05 and a power of 0.80. Allowing for 20 %
attrition, 592 participants would be necessary at baseline,
rounded to 600 for convenience.
Measures
Primary outcome: The primary outcome will be change
in cIMT over 24 months from randomization.
Secondary outcomes; will include progression of CKD,
death as a consequence of CKD/CVD, periodontal status,
endothelial function, arterial stiffness, measures of inflam-
mation and infection, CVD risk factors (blood pressure,
total cholesterol, HDL-cholesterol, HbA1c), CV events
(myocardial infarction, coronary revascularisation proce-
dures, ischaemic cerebrovascular disease, peripheral vas-
cular disease, ischaemic stroke) and oral health-related
quality of life. Progression of CKD will include time to the
development of the first of: (1) new development of
macroalbuminuria (defined as ACR ≥30 mg/mmol); (2)
30 % loss of baseline eGFR (defined as a reduction of
eGFR of 30 % or more from baseline and eGFR of less
than 60mLs/min/1.73 m2); (3) progression to ESKD
defined by eGFR <15 mLs/min; (4) progression to ESKD
defined by commencement of renal replacement therapy.
Data collection techniques
Both clinical and self-report information will be gathered
in this study.
Clinical: Each participant will receive CKD/CVD,
cardio-metabolic-related and dental assessments at four
time points throughout the study (baseline, 6 months,
12 months and 24 months post randomization).
CKD/CVD and cardio-metabolic-related assessments
Markers of renal function will be assessed by ACR
and eGFR. eGFR will be assessed using the CKD-EPI
formula: eGFR = 141 ×min(Scr × 0.0113/k, 1)α ×max(Scr ×
0.0113/k, 1)−1.209 × 0.993Age × 1.018 [if female], where Scr is
serum creatinine concentration in μmol/L, k is 0.7 for fe-
males and 0.9 for males, α is −0.329 for females and −0.411
for males, min indicates the minimum of Scr/k or 1 and
max indicates the maximum of Scr/k or 1. Maple-Brown
and colleagues demonstrated that the correction factor
“if black” is not applicable to Aboriginal Australians [47].
Markers of systemic inflammation will be assessed
by CRP, serum amyloid A, fibrinogen, neutrophils and
total IgG. Standard Framingham risk factors will be
assessed (non-fasting lipids, blood pressure, diabetes
control (HbA1c), BMI and tobacco smoking) as well as
waist-hip ratio and medications including ACE inhibitors
and angiotensin receptor blockers. Peripheral blood pres-
sure will be measured and central pressure calculated
(SphygmoCor XCEL).
Markers of cardiovascular health will be measured by:
(1) cIMT; (2) endothelial function; (3) arterial stiffness
and; (4) additional CVD risk factors.
1. Common carotid intima-media thickness (IMT)
External ultrasound of the common carotid artery
will be performed with the patient lying in a supine
position, neck slightly extended and the head tilted
45° away from the side being scanned whilst
connected to 3-lead ECG, to monitor cardiac cycle.
Bilateral longitudinal images of the carotid bulb and
common carotid artery, up to 10 mm proximal to the
bulb, will be obtained using a portable ultrasound
(Sonosite, Bothell, USA) with a 10–5 MHz linear
array transducer. Both the right and left carotid
arteries will each be scanned from three angles, with
two loops obtained from each scan angle, and stored
in a digital format for batch analysis by an observer
blinded to participant characteristics, randomization
and study visit. Measurement of carotid IMT will be
performed on the far wall of the common carotid
artery at end diastole, within 10 mm proximal to
the carotid bulb, from at least two consecutive
cardiac cycles.
2. Endothelial function—brachial artery flow-mediated
dilatation (FMD)
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High-resolution ultrasound will be used to assess
brachial artery diameter at rest, and after a
hyperaemic stimulus in response to a 5 min forearm
occlusion. A 30 s loop will be acquired at rest, and
three 30 s loops acquired post-hyperaemia from
30–60 s, 60–90 s, and 90–120 s. Response to sublingual
nitroglycerin, a smooth muscle dilator, will not be
determined to minimize participant burden.
3. Arterial stiffness—carotid-femoral pulse wave velocity
Pulse wave velocity along the aortic transit will be
assessed using a SphygmoCor XCEL device (Atcor
medical). This validated device assesses carotid and
femoral pulses concurrently by handheld tonometer
and thigh cuff, respectively. Distance from the
suprasternal notch to the two sites will be measured
immediately after data capture. Two measures of
pulse wave velocity will be made, with a 1 minute
interval.
4. History and incidence of cardiovascular and
cerebrovascular events will be defined as coronary
heart disease (myocardial infarction, angina pectoris,
coronary revascularisation procedures), ischaemic
cerebrovascular disease, peripheral vascular disease
and transient ischaemic attack.
Dental assessment: This will include tooth presence,
caries experience, periodontal destruction, gingivitis and
calculus, plaque, oral mucosal lesions and trauma.
Self-report Self-report information pertaining to socio-
demographic, oral health and general health factors will
be gathered at baseline.
Socio-demographic factors: These will include age, sex,
education level, employment, English-as-first-language,
house ownership, number of children and number of
people who stayed in house the previous night.
Oral health factors: These will include self-reported
oral health, oral health behaviours and oral health-
related quality of life.
General health factors: These will include behaviours
such as smoking and alcohol consumption, current
medication, current diagnoses (for diabetes, cardiovascular
disease, hypertension etc.), status of current diagnoses
(controlled, uncontrolled etc.) and stress (measured by an
adapted PHQ9 scale; a measure of distress that has been
validated for Aboriginal adults; [48]).
Reimbursement for time
As per our standard procedures for Aboriginal partici-
pants involved in periodontal interventions, all partici-
pants will receive a $AUS20 gift voucher at baseline,
3-, 6-, 12- and 24-month follow-up as reimbursement
for time. Each participant will additionally receive free
periodontal care and a sample bag of oral health-
related items.
Data analysis
Data analysis will use intention-to-treat and per-protocol
approaches, with the effect on primary outcomes based
on intention-to-treat analyses. Analyses will follow a
general course of descriptive statistics such as distributions
and measures of association. Simple cross-tabulations and
more elaborate repeated-measures analyses will follow.
In brief, the plan for the analysis of each aim is:
Aim 1: Extent and severity of periodontal disease
compared with national-level counterparts: Extent of
periodontal disease will be defined by the number of
periodontal sites in the mouth with a given pocket
depth (PD) divided by the number of teeth in the
mouth x 100. The National Survey of Adult Oral
Health dataset will enable comparison with both
general and Aboriginal population-level estimates [49].
General analysis will comprise Chi-square and Student’s
t-test within the study sample and non-overlapping
95 % confidence intervals when comparing with
population estimates.
Aim 2: Changes in cIMT, measures of renal function
and CKD/CVD-related death: The primary analysis
will compare changes in cIMT and 95 % confidence
intervals. Secondary analyses will examine each
outcome variable using separate mixed models, to
allow inclusion of all participants without having to
impute data. We will use generalised linear mixed
models for non-continuous outcomes. Models will
include treatment group as a fixed effect. Analyses will
be conducted to identify subgroups that modify the
response to the intervention (eg. active/passive smoking,
socio-economic status). Model assumptions will be
checked and appropriate adjustments made. We will
conduct sensitivity analyses to assess uncertainty in key
parameters. Death and cardiovascular events, both binary
outcomes, will be analysed using the chi-square test with
frequencies and percentages per treatment arm and
odds-ratios or other measures of treatment effect
reported along with summary measures. The
Greenhouse-Geisser correction for the F-test will be
used to adjust the degrees of freedom for deviation
from sphericity. Logarithmic transformation of the
data will be performed where appropriate. A post hoc
correlation analysis by the Spearman rank-correlation
method will be performed to evaluate the relationship
between the changes in renal function and cIMT from
baseline to 6, 12 and 24 months following periodontal
therapy. The same will also be done for measures of
periodontal health and cIMT. Effect sizes will be
calculated by dividing the mean of change scores by
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the pooled estimate of the standard deviation. Effect
measures will also be presented through calculation
of number-needed-to-treat and its associated 95 %
confidence interval. The statistically significant level
will be at α < 0.05.
Discussion
The proposed study will be the first RCT evaluating the
effect of periodontal therapy on progression of CKD and
CVD events among Aboriginal patients with CKD. The
proposed study will investigate a novel use for a widely
available public health service with which every health
professional is familiar. This innovative study will pro-
vide critical information regarding the progression of
renal disease and rates of cardiovascular events among
those with CKD, with endpoints used previously by
many highly cited RCTs that are international standards
used in everyday clinical practice. Demonstration of a
significant attenuation of CKD progression and CVD
events has the potential to inform clinicians of an im-
portant, new and widely available strategy for reducing
CKD progression and CVD events for Australia’s most
disadvantaged population.
As such, the Perio-CKD study will have significance for
policy and planning by providing evidence of the relation-
ship between periodontal therapy and cardiovascular dis-
ease among Indigenous Australian adults with chronic
kidney disease, and the effectiveness of an intervention
aimed at improving periodontal, renal and cardiovascular
health in an Indigenous population. Efforts to understand
and improve progression of renal disease among Indi-
genous Australians may serve as an important means
of reducing the gap between Indigenous and non-
Indigenous health.
The findings may help raise the profile of the role of
periodontal disease in cardiovascular and renal health;
thus increasing the knowledge base of those working
intimately with patients with chronic kidney disease.
Ultimately it is hoped that the findings might encourage
greater dialogue between oral health and medical profes-
sionals so that periodontal treatment might become a
routine part of care in the treatment of chronic kidney
disease among Indigenous as well as non-Indigenous
populations.
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